These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 27696263)

  • 41. [Novel agents in multiple myeloma treatment].
    Ito S
    Rinsho Ketsueki; 2015 Oct; 56(10):2066-73. PubMed ID: 26458446
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic advances in relapsed or refractory multiple myeloma.
    Anderson KC
    J Natl Compr Canc Netw; 2013 May; 11(5 Suppl):676-9. PubMed ID: 23704241
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma.
    Hajek R; Siegel D; Orlowski RZ; Ludwig H; Palumbo A; Dimopoulos M
    Leuk Lymphoma; 2014 Jan; 55(1):11-8. PubMed ID: 23614765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pomalidomide. A last-line treatment option for multiple myeloma.
    Prescrire Int; 2014 Nov; 23(154):257-9. PubMed ID: 25954788
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New pharmacotherapy options for multiple myeloma.
    Mina R; Cerrato C; Bernardini A; Aghemo E; Palumbo A
    Expert Opin Pharmacother; 2016; 17(2):181-92. PubMed ID: 26684262
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
    Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Practical Approaches to the Management of Dual Refractory Multiple Myeloma.
    Lee HC; Mark TM; Shah JJ
    Curr Hematol Malig Rep; 2016 Apr; 11(2):148-55. PubMed ID: 26898556
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emerging therapies for the treatment of relapsed or refractory multiple myeloma.
    Dimopoulos MA; San-Miguel JF; Anderson KC
    Eur J Haematol; 2011 Jan; 86(1):1-15. PubMed ID: 20942854
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Carfilzomib in multiple myeloma.
    Andreu-Vieyra C; Berenson JR
    Expert Opin Biol Ther; 2014 Nov; 14(11):1685-99. PubMed ID: 25170966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma.
    Terpos E; Kanellias N; Christoulas D; Kastritis E; Dimopoulos MA
    Onco Targets Ther; 2013; 6():531-8. PubMed ID: 23690693
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel therapies for relapsed myeloma.
    Stewart AK
    Hematology Am Soc Hematol Educ Program; 2009; ():578-86. PubMed ID: 20008242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sequencing multiple myeloma therapies with and after antibody therapies.
    van de Donk NWCJ
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):248-258. PubMed ID: 33275724
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
    Salvini M; Bonello F; Boccadoro M; Larocca A
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
    Sanchez L; Vesole DH; Richter JR; Biran N; Bilotti E; McBride L; Anand P; Ivanovski K; Siegel DS
    Br J Haematol; 2017 Feb; 176(3):440-447. PubMed ID: 27859001
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
    Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
    Huang WR; Li R; Jing Y; Zhang YZ; Wu XX; Gao CJ; Bo J; Yu L; Wang QS; Da WM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1146-50. PubMed ID: 17204182
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.
    Dimopoulos MA; Palumbo A; Attal M; Beksaç M; Davies FE; Delforge M; Einsele H; Hajek R; Harousseau JL; da Costa FL; Ludwig H; Mellqvist UH; Morgan GJ; San-Miguel JF; Zweegman S; Sonneveld P;
    Leukemia; 2011 May; 25(5):749-60. PubMed ID: 21293488
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
    Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
    Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.